NCT01468376

GLU-xx Formulations in Individuals With Impaired Glucose Tolerance

An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Afexa Life Sciences Inc · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.

Conditions

• Impaired Glucose Tolerance

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	GLU-01	14 day dosing
DIETARY_SUPPLEMENT	GLU-02	14 day dosing
DIETARY_SUPPLEMENT	GLU-03	14 day dosing
DIETARY_SUPPLEMENT	GLU-04	14 day dosing
DIETARY_SUPPLEMENT	GLU-05	14 day dosing
DIETARY_SUPPLEMENT	GLU-06	14 day dosing

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2011-11-09
• Last updated: 2012-01-31

Locations

1 site across 1 country: United States